Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in HIV+ Kidney Transplant Recipients
NCT02741323Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in kidney transplant rejection comparing Maraviroc with Placebo (2 arms). Primary endpoints: Mean Glomerular Filtration Rate by Iohexol Clearance at 52 weeks and Cumulative Incidence of Graft Loss, Toxicities >= Grade 3, or Permanent Treatment Discontinuation at 52 weeks. Started Jan 2017; status: completed.
02
Drugs
maraviroc
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02741323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741323.